Trials / Completed
CompletedNCT00205465
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (planned)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- —
Summary
To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-765 |
Timeline
- Start date
- 2004-12-01
- Completion
- 2005-09-01
- First posted
- 2005-09-20
- Last updated
- 2007-12-05
Source: ClinicalTrials.gov record NCT00205465. Inclusion in this directory is not an endorsement.